Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And

Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And

Sponsor(s)

Exelixis

Principal Investigator(s)John Kauh, MD
Dates10/27/2009 - 10/27/2013